Get the Stockscreener App
4.27
0.70%
-0.03
After Hours:
4.27
Humacyte Inc stock is traded at $4.27, with a volume of 1.34M.
It is down -0.70% in the last 24 hours and down -13.56% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$4.30
Open:
$4.32
24h Volume:
1.34M
Relative Volume:
0.31
Market Cap:
$549.41M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-3.9907
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
-9.53%
1M Performance:
-13.56%
6M Performance:
-48.55%
1Y Performance:
+16.99%
1-Day Range:
$4.22
$4.45
1-Week Range:
$4.20
$4.85
52-Week Range:
$2.81
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.27 | 549.41M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know - MSN
Investing in Humacyte Inc (HUMA) Is Getting More Attractive - Knox Daily
Financial Analysis: Humacyte Inc (HUMA)’s Ratios Unveil Key Insights - The Dwinnex
Examining Humacyte Inc (HUMA) more closely is necessary - US Post News
Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMAW) Trading Down 1% – What’s Next? - Defense World
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte and Pluristyx enhance partnership for diabetes treatment By Investing.com - Investing.com South Africa
Humacyte, Pluristyx Announce Gene Editing Partnership -January 28, 2025 at 12:05 pm EST - Marketscreener.com
Humacyte and Pluristyx enhance partnership for diabetes treatment - Investing.com India
Humacyte and Pluristyx Announces Gene Editing Partnership to Support BioVascular Pancreas (BVP?) Development Using iPSCs - Marketscreener.com
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs - The Manila Times
Revolutionary Diabetes Breakthrough: Gene-Edited Cell Technology Could End Daily Insulin Injections - StockTitan
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2 Firms Want To Co-Lead Humacyte Investor Suit - Law360
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Humacyte: Upside Potential, But I Will Wait For Revenue Trends - Seeking Alpha
Cantor Fitzgerald Comments on Humacyte FY2025 Earnings - Defense World
Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital - Defense World
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Cantor Fitzgerald Estimates Humacyte FY2025 Earnings - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte moves to test bioengineered vessel in heart surgery By Investing.com - Investing.com Australia
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Announces Planned IND Filing in 2025 to Support - GlobeNewswire
Humacyte Sends First Shipment of Human Acellular Vessels to Ukraine as Part of Humanitarian Efforts - Fresenius Medical Care
11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World
Humacyte (NASDAQ:HUMA) Stock Price Up 10%Time to Buy? - MarketBeat
Cantor Fitzgerald Boosts Earnings Estimates for Humacyte - Defense World
Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Humacyte (NASDAQ:HUMA) Stock Price Down 6.4%What's Next? - MarketBeat
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2 - GuruFocus.com
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - PR Newswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending - GlobeNewswire
Cantor Fitzgerald Predicts Higher Earnings for Humacyte - MarketBeat
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Ac - GuruFocus.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
2025-01-16 | HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:HUMA | Press Release - Stockhouse Publishing
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):